Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance (Rejuvenate2)

U

University of Exeter

Status

Terminated

Conditions

Impaired Mitochondrial Function, Muscle Performance

Treatments

Dietary Supplement: Placebo
Dietary Supplement: Acipimox

Study type

Interventional

Funder types

Other

Identifiers

NCT03325491
1617/024

Details and patient eligibility

About

As people grow older skeletal muscle gradually becomes smaller and weaker, causing reduced mobility and quality of life. To understand and reverse this negative process investigators need to find new ways of improving the ability of muscle to perform physical activity. There is some evidence that supplements may improve how the mitochondria work, and investigators want to explore this idea in more detail. This is possible by measuring how the muscles work and respond to exercise before and after taking the supplement alongside an aerobic (i.e. cycling) and resistance (i.e. weight lifting) exercise programme. This will give us the basic information investigators would need to see if this is a useful idea.

Enrollment

2 patients

Sex

Male

Ages

65 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male
  • Age between 65-75 years
  • Body mass index between 19-29
  • No active cardiovascular or metabolic disease
  • No active respiratory disease
  • No current musculoskeletal injuries
  • A sedentary lifestyle (i.e. does not engage in strenuous, planned physical activity)
  • The ability to give informed consent

Exclusion criteria

  • Currently taking a statin drug or NSAIDs
  • Have a current peptic ulcer
  • Have any renal impairment
  • Have a known hypersensitivity to Acipimox
  • Suffer from vertigo
  • Smoker

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

2 participants in 2 patient groups, including a placebo group

Acipimox plus exercise training
Experimental group
Description:
The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
Treatment:
Dietary Supplement: Acipimox
Placebo plus exercise training
Placebo Comparator group
Description:
The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems